The Aminobisphosphonate Risedronate Preserves Localized Mineral and Material Properties of Bone in the Presence of Glucocorticoids

OBJECTIVE. Glucocorticoids (GCs) alter bone strength such that patients receiving these medications have a high rate of fragility-related fractures. The purpose of this study was to assess whether concurrent treatment with GCs (prednisolone) and risedronate (an aminobisphosphonate) would prevent the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Rheum
Hlavní autoři: Balooch, Guive, Yao, Wei, Ager, Joel W., Balooch, Mehdi, Nalla, Ravi K., Porter, Alexandra E., Ritchie, Robert O., Lane, Nancy E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2007
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6913894/
https://ncbi.nlm.nih.gov/pubmed/17968931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.22976
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky